A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)

Health Technology Assessment

Volumn 19, Issue 78, 2015, Pages 1-298

  Chakravarthy, Usha ^a   Harding, Simon P ^b   Rogers, Chris A ^c   Downes, Susan ^d   Lotery, Andrew J ^e   Dakin, Helen A ^f   Culliford, Lucy ^c   Scott, Lauren J ^c   Nash, Rachel L ^c   Taylor, Jodi ^c   Muldrew, Alyson ^a   Sahni, Jayashree ^b   Wordsworth, Sarah ^f   Raftery, James ^e   Peto, Tunde ^g   Reeves, Barnaby C ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL INFECTION; ABDOMINAL PAIN; ABDOMINAL WALL HERNIA; ABNORMAL SENSATION; ACUTE PANCREATITIS; AGE RELATED MACULAR DEGENERATION; AGED; ALLERGIC CONJUNCTIVITIS; ANGINA PECTORIS; ANKLE FRACTURE; ANORECTAL DISEASE; ANUS FISSURE; AORTA THROMBOSIS; ARTHRALGIA; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; BENIGN TUMOR; BLADDER TUMOR; BLEEDING; BLEPHARITIS; BLEPHAROSPASM; BLINDNESS; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; BLURRED VISION; BRADYCARDIA; BREAST CANCER; BREAST DISEASE; BURN; CARTILAGE INJURY; CATARACT; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHALAZION; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PANCREATITIS; CLAVICLE FRACTURE; CLINICAL EFFECTIVENESS; COLITIS; COLON CANCER; COLOR BLINDNESS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTRAST SENSITIVITY; CONTROLLED STUDY; CONTUSION; COR PULMONALE; CORNEA DISEASE; CORNEA DYSTROPHY; CORNEA EROSION; CORNEA PERFORATION; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DACRYOCYSTITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DIPLOPIA; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY EYE; DUODENUM ULCER; DYSPEPSIA; DYSPHAGIA; DYSPNEA; EAR DISEASE; ENDOCRINE DISEASE; ENDOPHTHALMITIS; EPICONDYLITIS; EPISCLERITIS; ESOPHAGITIS; ESOPHAGUS CARCINOMA; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; EXOPHTHALMOS; EYE DISCHARGE; EYE INFECTION; EYE INFLAMMATION; EYE INJURY; EYE IRRITATION; EYE PAIN; EYE SWELLING; EYELID EDEMA; EYELID PAIN; FACE INJURY; FACIAL NERVE PARALYSIS; FACTORIAL DESIGN; FALLING; FECES IMPACTION; FECES INCONTINENCE; FEMALE; FEMUR FRACTURE; FIBROSIS; FOLLOW UP; FOOT FRACTURE; FOREIGN BODY; FRACTURE; FRONTOTEMPORAL DEMENTIA; GALLBLADDER CANCER; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC ATROPHY; GINGIVA DISEASE; GINGIVA PAIN; GLAUCOMA; GLOSSITIS; HAND FRACTURE; HEALTH UTILITIES INDEX VERSION 3; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMATOMA; HEMATURIA; HEMOPERICARDIUM; HEMORRHOID; HERPES ZOSTER; HIATUS HERNIA; HIP FRACTURE; HORDEOLUM; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; HYPONATREMIA; INFECTION; INJURY; INNER EAR DISEASE; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRRITABLE COLON; JAUNDICE; JOINT DISLOCATION; KERATITIS; KIDNEY DISEASE; KIDNEY FAILURE; LACERATION; LIMB FRACTURE; LIMB INJURY; LIVER CANCER; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; LUNG EDEMA; LUNG EMBOLISM; LUNG EMPHYSEMA; LYMPHATIC SYSTEM DISEASE; MACULAR DEGENERATION; MACULAR DISEASE DEPENDENT QUALITY OF LIFE; MACULAR DISEASE TREATMENT SATISFACTION QUESTIONNAIRE; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MEDIASTINUM DISEASE; MENIERE DISEASE; MENTAL DISEASE; MESOTHELIOMA; METABOLIC DISORDER; METAMORPHOPSIA; METASTASIS; MICROCYTIC ANEMIA; MITRAL VALVE REGURGITATION; MOUTH EDEMA; MOUTH INJURY; MOUTH ULCER; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCLE STRAIN; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYDRIASIS; NAUSEA; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NOSE POLYP; NUTRITIONAL DISORDER; OCULAR PRURITUS; OPTICAL COHERENCE TOMOGRAPHY; ORTHOSTATIC HYPOTENSION; OVARY CANCER; OVARY CYST; PANCREAS CARCINOMA; PANCREAS CYST; PANCREATITIS; PELVIS FRACTURE; PHOTOPHOBIA; PNEUMONIA; POSTMENOPAUSE BLEEDING; PRESYNCOPE; PROSTATE CANCER; PTOSIS; PUNCTATE KERATITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM PROLAPSE; RESPIRATORY TRACT DISEASE; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA EDEMA; RETINA HEMORRHAGE; RETINA MACULOPATHY; RETINA TEAR; RETINA VEIN OCCLUSION; RETINAL THICKNESS; RIB FRACTURE; SHOCK; SIDE EFFECT; SKIN DISEASE; SPRAIN; STOMACH DISEASE; SUBDURAL HEMATOMA; SUBRETINAL NEOVASCULARIZATION; SUDDEN DEAFNESS; SUPRAVENTRICULAR TACHYCARDIA; SWELLING; TACHYCARDIA; THORAX DISEASE; THROMBOCYTOPENIA; TOOTH DISEASE; TOOTH PAIN; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; TRANSITIONAL CELL CARCINOMA; TRAUMATIC CATARACT; TRIPLE BLIND PROCEDURE; ULCERATIVE COLITIS; UNITED KINGDOM; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; UVEITIS; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULITIS; VISUAL ACUITY; VISUAL FIELD DEFECT; VISUAL HALLUCINATION; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; VOMITING; WRIST FRACTURE; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; NATIONAL HEALTH SERVICE; PHYSIOLOGY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RANIBIZUMAB; STATE MEDICINE; UNITED KINGDOM; VASCULAR ENDOTHELIAL GROWTH FACTORS; VISUAL ACUITY;

EID: 84943754270     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19780     Document Type: Article

References (132)

1. National Institute for Health and Care Excellence (NICE). Photodynamic Therapy for Age-related Macular Degeneration. NICE technology appraisal 68. London: NICE; 2003.
2. Dong LM, Marsh MJ, Hawkins BS. Measurement and analysis of visual acuity in multicenter randomized clinical trials in the United States: findings from a survey. Ophthalmic Epidemiol 2003;10:149-56. http://dx.doi.org/10.1076/opep.10.3.149.15080
3. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001;119:198-207.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16. http://dx.doi.org/10.1056/NEJMoa042760
5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45. http://dx.doi.org/10.1001/archopht.117.10.1329
6. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. http://dx.doi.org/10.1097/01.iae.0000242842. 14624.e7
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. http://dx.doi.org/10.1056/NEJMoa062655
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. http://dx.doi.org/ 10.1056/NEJMoa054481
9. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
10. Anon. Variable Dosing of Ranibizumab Investigated for Treatment of Neovascular AMD Ophthalmology Times. URL: http://ophthalmologytimes.modernmedicine.com/ophthalmology times/news/clinical/ophthalmology/variable-dosing-ranibizumab-investigated-treatment-ne (accessed 18 June 2015).
11. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90. http://dx.doi.org/10.1097/00006982-200604000-00001
12. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-12.
13. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.e5. http://dx.doi.org/10.1016/j.ophtha.2005.11.019
14. Kilic U, Kilic E, Jarve A, Guo Z, Spudich A, Bieber K, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 2006;26:12439-46. http://dx.doi.org/10.1523/JNEUROSCI.0434-06.2006
15. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci 2006;47:3135-42. http://dx.doi.org/10.1167/iovs.05-1229
16. Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508.e1-25.
17. Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci 2005;360:1617-38. http://dx.doi.org/10.1098/rstb.2005.1693
18. Pasqualetti G, Danesi R, Del Tacca M, Bocci G. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007;8:49-66. http://dx.doi.org/10.2217/14622416.8.1.49
19. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006;38:1055-9. http://dx.doi.org/10.1038/ng1873
20. Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006;38:1173-7. http://dx.doi.org/10.1038/ng1890
21. Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314:989-92. http://dx.doi.org/10.1126/ science.1133807
22. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98. http://dx.doi.org/10.1016/j.ophtha.2012.03.053
23. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908. http://dx.doi.org/10.1056/NEJMoa1102673
24. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33. http://dx.doi.org/10.1167/iovs.04-0601
25. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25. http://dx.doi.org/10.1345/aph.1H316
26. The IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411. http://dx.doi.org/10.1016/j.ophtha.2012.04.015
27. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6. http://dx.doi.org/10.1016/0002-9394(82)90197-0
28. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 1988;2:187-99.
29. Bailey IL, Lovie JE. The design and use of a new near-vision chart. Am J Optom Physiol Opt 1980;57:378-87. http://dx.doi.org/10.1097/00006324-198006000-00011
30. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, et al. Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol 2002;120:1029-38. http://dx.doi.org/10.1001/ archopht.120.8.1029
31. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 2000;84:244-50. http://dx.doi.org/10.1136/bjo.84.3.244
32. Williams AE. A new facility for the measurement of health-related quality-of-life. Health Policy 1990;16:199-208. http://dx.doi.org/10.1016/0168-8510(90)90421-9
33. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, De Pauw S, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:113-28. http://dx.doi.org/10.1097/00005650-200202000-00006
34. Mitchell J, Bradley C. Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Qual Life Res 2004;13:1163-75. http://dx.doi.org/10.1023/ B:QURE.0000031348.51292.4a
35. Mitchell J, Brose L, Bradley C. Design of a measure of satisfaction with treatment for macular degeneration (MacTSQ). Qual Life Res 2007;A120(Suppl.):A1150.
36. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. http://dx.doi.org/10.1136/ bmj.308.6921.81
37. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum; 1988.
38. Reeves BC, Wood JM, Hill AR. Reliability of high- and low-contrast letter charts. Ophthalmic Physiol Opt 1993;13:17-26. http://dx.doi.org/10.1111/j.1475-1313.1993.tb00421.x
39. The Association for Research in Vision and Ophthalmology (ARVO) Annual Conference 2011. Fluctuating Levels of Circulating VEGF in a Subset of Patients as Part of the Multicentre IVAN Study. 2011. URL: www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2684& sKey=9009b5e8-692c-4edb-9d05-f2eeb2af05eb&cKey=bd842624-68d2-4b65-b3ba- 5a13c840fc5d&mKey=6f224a2d-af6a-4533-8bbb-6a8d7b26edb3 (accessed 3 June 2015).
40. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, Group C. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308:2594-604. http://dx.doi.org/10.1001/jama.2012.87802
41. International Conference on Harmonisation (ICH). ICH Harmonised Tripartite Guideline Topic E9: Statistical Principles for Clinical Trials. URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (accessed 16 January 2014).
42. Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9. http://dx.doi.org/ 10.1016/j.ophtha.2013.06.020
43. Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71. http://dx.doi.org/10.1136/bjophthalmol-2012-302391\
44. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, Daly MK, et al. Bevacizumab vs. ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye 2010;24:1708-15. http://dx.doi.org/10.1038/eye.2010.147
45. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk/media/D45/1E/ GuideToMethodsTechnologyAppraisal2013.pdf (accessed 17 May 2013).
46. Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med 1989;8:161-71. http://dx.doi.org/10.1002/sim.4780080204
47. Byar DP, Piantadosi S. Factorial designs for randomized clinical trials. Cancer Treat Res 1985;69:1055-63. http://dx.doi.org/10.1016/0197-2456(85)90010-8
48. Van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom 2008;91:427-37. http://dx.doi.org/10.1111/j.1444-0938.2008.00305.x
49. La Cour M. Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? Acta Ophthalmol Scand 2007;85:2-4. http://dx.doi.org/10.1111/j.1600-0420.2006.00869.x
50. Penha FM, Rodrigues EB, Maia M, Furlani BA, Regatieri C, Melo GB, et al. Retinal and ocular toxicity in ocular application of drugs and chemicals - part II: retinal toxicity of current and new drugs. Ophthalmic Res 2010;44:205-24. http://dx.doi.org/10.1159/000316695
51. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 62, September 2011. London: BMA and RPS; 2011.
52. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289:2545-53. http://dx.doi.org/10.1001/jama.289.19.2545
53. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn. New York, NY: Oxford University Press; 2005.
54. Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ 2013;22:22-34. http://dx.doi.org/10.1002/hec.1812
55. Gudex C, editor. Time Trade-off User Manual: Props and Self-completion Methods. York: University of York, Centre for Health Economics; 1994. URL: www.york.ac.uk/inst/che/pdf/ op20.pdf (accessed 3 June 2015).
56. Williams A. The Measurement and Valuation of Health: A Chronicle. The University of York diiscussion paper 136. York: University of York; 1995.
57. National Institute for Health and Care Excellence (NICE). Social Value Judgements: Principles for the Development of NICE Guidance. 2nd edn. London: NICE; 2008. URL: www.nice.org.uk/media/ C18/30/SVJ2PUBLICATION2008.pdf (accessed 31 May 2012).
58. Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied Methods of Cost-Effectiveness Analysis in Health Care. Oxford: Oxford University Press; 2011.
59. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87. http://dx.doi.org/10.1002/hec.635
60. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. http://dx.doi.org/10.1097/00005650-199711000-00002
61. Szende A, Williams A, editors. Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D. Rotterdam: EuroQol Group; 2004.
62. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. PharmacoEconomics 1995;7:490-502. http://dx.doi.org/10.2165/00019053- 199507060-00004
63. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health Utilities Index. PharmacoEconomics 1995;7:503-20. http://dx.doi.org/10.2165/00019053-199507060-00005
64. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for Euroqol: Results from a UK General Population Survey. Centre for Health Economics discussion paper 138. York: Centre for Health Economics, University of York; 1995.
65. Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review. Int J Technol Assess Health Care 2006;22:235-41. http://dx.doi.org/10.1017/ S0266462306051051
66. Espallargues M, Czoski-Murray CJ, Bansback NJ, et al. The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci 2005;46:4016-23. http://dx.doi.org/10.1167/iovs.05-0072
67. Tosh J, Brazier J, Evans P, Longworth L. A Review of Generic Preference-based Measures of Health-related Quality of Life in Visual Disorders. Sheffield: Health Economics and Decision Science, University of Sheffield; 2011. URL: http://eprints.whiterose.ac.uk/42935/1/ HEDS_DP_11-03.pdf (accessed 21 September 2011).
68. Feeny DH, Torrance GW, Furlong WJ. Health Utilities Index. In Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd edn. Philadelphia, PA: Lippincott-Raven Press; 1996. pp. 239-52.
69. Furlong W, Feeny D, Torrance GW, Goldsmith CH, DePauw S, Zhu Z, et al. Multiplicative Multi-Attribute Utility Function for the Health Utilities Index Mark 3 (HUI3) System: A Technical Report. McMaster University Centre for Health Economics and Policy Analysis Working Paper No 98-11. Hamilton, ON: McMaster University Centre for Health Economics and Policy Analysis; 1998. URL: http://fhsmcmasterca/hug/wp9811htm (accessed 3 June 2015).
70. Luyten J, Marais C, Hens N, De Schrijver K, Beutels P. Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. Value Health 2011;14:282-90. http://dx.doi.org/10.1016/j.jval.2010.10.004
71. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. PharmacoEconomics 2005;23:619-37. http://dx.doi.org/10.2165/00019053-200523060-00008
72. Jonsson B, Weinstein MC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. Int J Technol Assess Health Care 1997;13:49-58. http://dx.doi.org/ 10.1017/S0266462300010229
73. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. http://dx.doi.org/ 10.1136/bmj.313.7052.275
74. National Institute for Health and Care Excellence (NICE). Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration TA155 (revised). London: NICE; 2012. URL: www. nice.org.uk/nicemedia/live/12057/41719/41719.pdf (accessed 14 June 2013).
75. Department of Health (DH). National Schedule of Reference Costs 2010-11 for NHS Trusts and PCTs Combined. London: DH; 2011. URL: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/ documents/digitalasset/dh_131148.xls (accessed 18 January 2012).
76. Department of Health (DH). PbR Operational Guidance and Tariffs: 2011-12 Tariff Information Spreadsheet. London: DH; 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_124356 (accessed 8 August 2012).
77. Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: PSSRU, University of Kent; 2011. URL: www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf (accessed 1 February 2012).
78. Health and Social Care Information Centre (HSCIC). NHS Staff Earnings January - March 2011. HSCIC; 2011. URL: www.hscic.gov.uk/catalogue/PUB00825/nhs-staf-earn-jan-mar-2011-tab.xls (accessed 16 January 2011).
79. Yu LM, Burton A, Rivero-Arias O. Evaluation of software for multiple imputation of semi-continuous data. Stat Methods Med Res 2007;16:243-58. http://dx.doi.org/10.1177/0962280206074464
80. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing … presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:377-92. http://dx.doi.org/10.1002/hec.766
81. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99. http://dx.doi.org/10.1002/sim.4067
82. Royston P. Multiple imputation of missing values. STATA J 2004;4:227-41.
83. Royston P. Multiple imputation of missing values: update of ice. STATA J 2005;5:527-36.
84. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring. STATA J 2007;7:445-64.
85. De Clercq C, Snyers B, Guagnini AP, Kozyreff A. [Treatment of age-related macular degeneration with intravitreous injections of bevacizumab (Avastin): short-term results.] Bull Soc Belge Ophthalmol 2007:15-21.
86. Hallstrom AP, Sullivan SD. On estimating costs for economic evaluation in failure time studies. Med Care 1998;36:433-6. http://dx.doi.org/10.1097/00005650-199803000-00019
87. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34. http://dx.doi.org/10.2307/2533947
88. Montgomery AA, Peters TJ, Little P. Design, analysis and presentation of factorial randomised controlled trials. BMC Med Res Methodol 2003;3:26. http://dx.doi.org/10.1186/1471-2288-3-26
89. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487-96. http://dx.doi.org/10.1002/hec.944
90. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: TSO; 2003.
91. National Institute for Health and Care Excellence (NICE). Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration. NICE technology appraisal 155. London: NICE; 2008. URL: www.nice.org.uk/nicemedia/pdf/TA155guidance.pdf (accessed 31 October 2011).
92. Reeves BC, Harding SP, Langham J, Grieve R, Tomlin K, Walker J, et al. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK. Health Technol Assess 2012;16(6). http://dx.doi.org/10.3310/hta16060
93. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67. http://dx.doi.org/10.1016/ S0140-6736(13)61501-9
94. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D. York: Centre for Health Economics; 1999.
95. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001;10:179-84. http://dx.doi.org/10.1002/hec.584
96. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908. http://dx.doi.org/10.1056/NEJMoa1102673
97. Alsheikh-Ali AA, Karas RH. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol 2008;101:9-13B. http://dx.doi.org/10.1016/ j.amjcard.2008.02.027
98. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6. http://dx.doi.org/10.1136/ bjo.2007.116616
99. Raftery J, Dent L. Should avastin be used to treat age-related macular degeneration in the NHS? - Yes. Eye 2009;23:1247-9. http://dx.doi.org/10.1038/eye.2009.85
100. National Institute for Health and Care Excellence (NICE). Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration TA155: Costing Template and Report. London: NICE; 2008. URL: www.nice.org.uk/nicemedia/live/12057/41735/41735.xls (accessed 27 February 2012).
101. Williams T, Reeves BC, Foss AJ, Fell G. Risks of adverse events with therapies for age-related macular degeneration: a response. Arch Ophthalmol 2012;130:124-5; author reply 5-6. http://dx.doi.org/10.1001/archopht.130.1.124
102. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLOS ONE 2012;7:e42701. http://dx.doi.org/10.1371/journal.pone.0042701.
103. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010;21:218-26. http://dx.doi.org/10.1097/ ICU.0b013e3283386783
104. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9. http://dx.doi.org/10.1001/archophthalmol.2010.223
105. Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203. http://dx.doi.org/10.1136/bmj.e4203.
106. Kemp A, Preen DB, Morlet N, Clark A, McAllister IL, Briffa T, et al. Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study. Retina 2013;33:920-7. http://dx.doi.org/10.1097/IAE.0b013e318276e07b
107. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42. http://dx.doi.org/10.1001/ archopht.124.11.1532
108. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48. http://dx.doi.org/10.1016/j.ophtha.2012.09.006
109. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.e1. http://dx.doi.org/10.1016/j.ajo.2010.04.011.
110. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000;118:47-51. http://dx.doi.org/10.1001/archopht.118.1.47
111. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473-511.
112. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92. http://dx.doi.org/10.1016/S0167-6296(01)00130-8
113. Silva R, Axer-Siegel R, Eldem B, Kirchhof B, Papp A, Seres A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 2013;120:130-9. http://dx.doi.org/10.1016/j.ophtha.2012.07.026
114. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012;119:1175-83. http://dx.doi.org/10.1016/j.ophtha.2011.12.016
115. Dugel PU, Bebchuk JD, Nau J, Smith KR, Petrarca R, Slakter JS, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013;120:317-27. http://dx.doi.org/10.1016/j.ophtha.2012.07.068
116. Petrarca R, Jackson TL. Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2011;5:57-63. http://dx.doi.org/10.2147/OPTH.S16444
117. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48. http://dx.doi.org/10.1016/ j.ajo.2007.10.004
118. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71. http://dx.doi.org/10.1016/ j.ophtha.2010.12.019
119. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9. http://dx.doi.org/ 10.1016/j.ophtha.2010.09.004
120. Griffin SC, Barber JA, Manca A, Sculpher MJ, Thompson SG, Buxton MJ, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007;334:624. http://dx.doi.org/10.1136/bmj.39129.442164.55
121. Browne J, Jamieson L, Lewsey J, van der Meulen J, Black N, Cairns J, et al. Patient Reported Outcome Measures (PROMs) in Elective Surgery: Report to the Department of Health. London: London School of Hygiene and Tropical Medicine; 2007.
122. Longworth L, Yang YL, Young T, Mulhern B, Hernández Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess 2014;18(9). http://dx.doi.org/10.3310/hta18090
123. European Medicines Agency Committee for Medicinal Products for Human Use. CHMP Assessment Report: Eylea aflibercept. London: European Medicines Agency; 2012.
124. Ganiats TG, Browner DK, Kaplan RM. Comparison of two methods of calculating quality-adjusted life years. Qual Life Res 1996;5:162-4. http://dx.doi.org/10.1007/BF00435981
125. Billingham LJ, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3(10).
126. Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value Health 2012;15:118-27. http://dx.doi.org/ 10.1016/j.jval.2011.08.002
127. Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: PSSRU, University of Kent; 2010. URL: www.pssru.ac.uk/pdf/uc/uc2011/uc2011.pdf (accessed 17 January 2012).
128. Smith D. Community pharmacists and health promotion: a study of consultations between pharmacists and clients. Health Promot Int 1992;7:249-55. http://dx.doi.org/10.1093/heapro/ 7.4.249
129. O'Hagan A, Stevens JW. On estimators of medical costs with censored data. J Health Econ 2004;23:615-25. http://dx.doi.org/10.1016/j.jhealeco.2003.06.006
130. Lubsen J, Pocock SJ. Factorial trials in cardiology: pros and cons. Eur Heart J 1994;15:585-8.
131. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64. http://dx.doi.org/10.1016/ S0167-6296(98)00039-3
132. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40. http://dx.doi.org/10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W